Drug Profile
Research programme: dengue antibody therapeutics - A*STAR/Chugai Pharmaceutical
Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Agency for Science, Technology and Research; Chugai Pharmaceutical
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Dengue in Japan (Parenteral)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Dengue in Singapore (Parenteral)
- 29 Mar 2019 Chugai Pharmaceutical and A*STAR receives grant from Global Health Innovative Technology Fund (GHIT) for the development of anti-dengue virus antibody